From the Journals

Among asymptomatic, 2% may harbor 90% of community’s viral load: Study


 

Preceding the COVID-19 vaccine era

It should be noted that the research was conducted in fall 2020, before access to COVID-19 immunization.

“The study was performed prior to vaccine availability in a cohort of young people. It adds further data to support prior observations that the majority of infections are spread by a much smaller group of individuals,” David Hirschwerk, MD, said in an interview.

“Now that vaccines are available, I think it is very likely that a repeat study of this type would show diminished transmission from vaccinated people who were infected yet asymptomatic,” added Dr. Hirschwerk, an infectious disease specialist at Northwell Health in New Hyde Park, N.Y., who was not affiliated with the research.

Mechanism still a mystery

“This finding has been in the literature in piecemeal fashion since the beginning of the pandemic,” Dr. Sawyer said. “I just think we were the first to realize the bigger implications of these plots of viral load that we have all been seeing over and over again.”

How a minority of people walk around asymptomatic with a majority of virus remains unanswered. Are there special people who can harbor these extremely high viral loads? Or do many infected individuals experience a short period of time when they carry such elevated levels?

The highest observed viral load in the current study was more than 6 trillion virions per mL. “It is remarkable to consider that this individual was on campus and reported no symptoms at our testing site,” the researchers wrote.

In contrast, the lowest viral load detected was 8 virions per mL.

Although more research is needed, the investigators noted that “a strong implication is that these individuals who are viral ‘super carriers’ may also be ‘superspreaders.’ ”

Some of the study authors have financial ties to companies that offer commercial SARS-CoV-2 testing, including Darwin Biosciences, TUMI Genomics, Faze Medicines, and Arpeggio Biosciences.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Moderna announces first data showing efficacy of COVID-19 vaccine booster in development
MDedge Neurology
Dr. Topol talks: COVID-19 variants are innocent until proven guilty
MDedge Neurology
NSAIDs don’t make COVID-19 worse in hospitalized patients
MDedge Neurology
FDA authorizes Pfizer COVID vaccine for teens 12-15
MDedge Neurology
Dr. Fauci: Feds may ease indoor mask mandates soon
MDedge Neurology
What to know about COVID-19 vaccines and skin reactions
MDedge Neurology
Reassuring data on impact of mild COVID-19 on the heart
MDedge Neurology
CDC recommends use of Pfizer’s COVID vaccine in 12- to 15-year-olds
MDedge Neurology
Canned diabetes prevention and a haunted COVID castle
MDedge Neurology
CDC: Vaccinated? You don’t need a mask indoors
MDedge Neurology